

CITATION REPORT

List of articles citing

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer

DOI: 10.3390/biomedicines10082045
, 2022, 10, 2045.

Source: <https://exaly.com/paper-pdf/150232469/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities. 2023 , 11, e145-e154		2
3	Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China. 13,		0
2	Current Updates in Management of HER2-Positive and HER2-Low Breast Cancer.		0
1	Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.		0